Compare STGW & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STGW | TXG |
|---|---|---|
| Founded | 1980 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 2019 |
| Metric | STGW | TXG |
|---|---|---|
| Price | $5.84 | $17.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | $8.46 | ★ $14.73 |
| AVG Volume (30 Days) | 1.4M | ★ 2.6M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1954.71 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $2,890,264,000.00 | $641,814,000.00 |
| Revenue This Year | $4.53 | $4.50 |
| Revenue Next Year | $7.81 | N/A |
| P/E Ratio | $102.15 | ★ N/A |
| Revenue Growth | ★ 6.75 | 1.92 |
| 52 Week Low | $4.03 | $6.78 |
| 52 Week High | $7.66 | $20.34 |
| Indicator | STGW | TXG |
|---|---|---|
| Relative Strength Index (RSI) | 64.09 | 56.42 |
| Support Level | $5.51 | $17.32 |
| Resistance Level | $5.79 | $19.29 |
| Average True Range (ATR) | 0.20 | 1.07 |
| MACD | 0.05 | -0.21 |
| Stochastic Oscillator | 95.30 | 37.35 |
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).